meeting-slide1
meeting-slide2

Our Mission

The Consortium brings together international pediatric gastroenterologists and scientists from academic centers to identify the causes of Very Early Onset Inflammatory Bowel Disease (VEO-IBD) in order to develop new treatments for children with these rare diseases.

Our Strategy

In order to understand the molecular basis of VEO-IBD and to develop individualized treatments, we established the international interdisciplinary Very Early Onset Inflammatory Bowel Disease (VEO-IBD) Consortium, comprising 13 leading experts in the fields of basic and clinical research.

The VEO-IBD Consortium partners with over 100 clinical and academic centers worldwide and fosters collaborative interactions with its members in order to facilitate diagnosis and develop treatment strategies.

Our Research

patient-care1

Patient enrollment enables us to:

  • Identify the genetic variants responsible for VEO-IBD and define the molecular networks which are disrupted as a result of these variants.
  • Create an innovative Pediatric VEO-IBD Portal for Personalized Patient Care (P4Care) to develop tailored treatments for VEO-IBD patients.
  • Determine environmental factors affecting genetic and immunologic pathways relevant to VEO-IBD.

Founding Members

Principal Investigators

Aleixo Muise, MD, PHD

  • Co-Director, IBD Centre
  • Staff Clinician – Scientist
    Hospital for Sick Children
    University of Toronto
    Canada

Christoph Klein, MD, PHD

  • Chair, Department of Pediatrics
  • Director, Care-For-Rare Laboratories
    Dr. von Hauner Children’s Hospital
    Ludwig Maximilians University
    Munich
    Germany

Scott B. Snapper, MD, PHD

  • Wolpow Family Chair in IBD Treatment and Research
  • Director, IBD Center
    Boston Children’s Hospital
    Harvard Medical School
    U.S.A

Founding Investigators

  • Judy Cho, MD

    Ruth Ward-Coleman Professor in Translational Genetics, Medicine and Gastroenterology; Vice-Chair, Genetics and Gastroenterology, Mount Sinai School of Medicine, NYC

  • Hans Clevers, MD, PhD

    Director of the Hubrecht Institute, Utrecht, The Netherlands

  • Lynn Goldman, MD

    Michael and Lori Milken Dean of Public Health, George Washington University, DC

  • Dermot McGovern, MD, PhD

    Director, Translational Medicine, Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Hospital, LA

  • Ruslan Medzhitov, PhD

    Professor of Immunobiology; Investigator, Howard Hughes Medical Institute, Yale University

  • Josef Penninger, MD

    Senior Scientist and Scientific Director, Institute of Molecular Biotechnology, Austria

  • Fiona Powrie, PhD

    Chair in Gastroenterology, Head of Nuffield Department of Medicine – Experimental Medicine, University of Oxford

  • David Relman, MD

    Professor, Department of Microbiology & Immunology, Stanford University School of Medicine, CA

  • Eric Schadt, PhD

    Chair of the Department of Genetics and Genomics Sciences, Director of the Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, NYC

  • Dan Turner, MD, PhD

    Head of the Pediatric Gastroenterology and Nutrition Unit at Shaare Zedek Hospital, Jerusalem, Israel.

Collaboration Partners

© Copyright - VEO-IBD Consortium